Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.82 -2.78 (-9.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

3 Under-the-Radar Healthcare Companies

November 11, 2024

While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.

Via MarketBeat

A Preview Of Travere Therapeutics's Earnings ↗

October 30, 2024

Via Benzinga

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' ↗

October 23, 2024

Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.

Via Benzinga

Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) ↗

October 21, 2024

Via Benzinga

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views ↗

October 16, 2024

Via Benzinga

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs ↗

October 10, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 17, 2024

Via Benzinga

Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease ↗

October 09, 2024

The company could soon ask for approval of its only drug, Filspari, in a second disease.

Via Investor's Business Daily

Where Travere Therapeutics Stands With Analysts ↗

September 27, 2024

Via Benzinga

Micron To $150? Here Are 10 Top Analyst Forecasts For Friday ↗

September 27, 2024

Via Benzinga

Costco, Scholastic And 3 Stocks To Watch Heading Into Friday ↗

September 27, 2024

Via Benzinga

Analyst Ratings For Travere Therapeutics ↗

September 06, 2024

Via Benzinga

Expert Ratings For Travere Therapeutics ↗

August 02, 2024

Via Benzinga

Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts ↗

May 07, 2024

Via Benzinga

Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know ↗

April 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 26, 2024

Via Benzinga

This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 09, 2024

Via Benzinga

Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday ↗

September 06, 2024

Via Benzinga

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease ↗

September 06, 2024

The company previously had an accelerated approval for its IgA nephropathy treatment.

Via Investor's Business Daily

NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 06, 2024

Via Benzinga

Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights ↗

March 13, 2024

Via Benzinga

Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗

February 16, 2024

Via Benzinga

Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗

July 27, 2024

Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

July 10, 2024

Via Benzinga

Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗

July 09, 2024

Via Benzinga

TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 06, 2024

TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Earnings Preview For Travere Therapeutics ↗

February 14, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics ↗

January 18, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

Headline News about Travere Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today